Phase 3RecruitingAge-related condition
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
- Sponsor
- Ocugen (Industry)
- Enrollment
- 237 planned
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- OCU410
- Ages
- adults, older adults
- Registry
- NCT07770828
Full record on ClinicalTrials.gov
From the registry
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Primary outcomes
- Rate of change (slope) of square root-transformed GA lesion area from baseline to Month 12
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started